Skip to content
Peptide research

Retatrutide

Also known as LY3437943
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic triple-hormone peptide (GLP-1, GIP, glucagon) marketed for record-setting weight loss and metabolic improvement. Human evidence is strong: major weight loss, liver fat reduction, and blood sugar gains, though secondary benefits are less certain. GI side effects are common, long-term safety data are limited, and a theoretical thyroid tumor risk applies to the class. Not FDA-approved; most supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Retatrutide (LY3437943) is a first-in-class triple-hormone receptor agonist developed by Eli Lilly that simultaneously activates the GIP, GLP-1, and glucagon receptors. Administered as a once-weekly subcutaneous injection, it has produced the largest weight reductions ever recorded in obesity drug trials — up to 24.2% at 48 weeks in Phase 2 and 28.7% at 68 weeks in Phase 3. It is also being studied for type 2 diabetes, fatty liver disease (MASLD), knee osteoarthritis, and obstructive sleep apnea.

How it works in the body

A 'triple G' agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. GLP-1 suppresses appetite and improves blood sugar. GIP enhances the GLP-1 effect and may directly reduce fat storage. Glucagon increases energy expenditure and fat burning in the liver. The triple action produces dramatic weight loss.

Research overview

Retatrutide is the most advanced triple GIP/GLP-1/glucagon receptor agonist in clinical development. Its Phase 1b proof-of-concept trial in 72 people with type 2 diabetes (Urva et al., Lancet 2022) demonstrated safety and ~10% weight reduction at 12 mg over 12 weeks. Two landmark Phase 2 trials were published in 2023: Jastreboff et al. (NEJM, n=338 with obesity) showed dose-dependent weight loss up to 24.2% at 48 weeks with the 12 mg dose, with the weight loss curve still declining and no plateau observed; and Rosenstock et al. (Lancet, n=281 with T2D) showed HbA1c reductions up to 2.02% and weight loss up to 16.9% at 36 weeks. A MASLD substudy (Sanyal et al., Nature Medicine 2024, n=98) demonstrated liver fat reductions of 82-86% at the 8-12 mg doses, with 86% achieving normal liver fat levels at 24 weeks. The Phase 3 TRIUMPH program launched in 2023 and encompasses 8+ trials enrolling over 5,800 participants. TRIUMPH-4 (n=445, knee OA) was the first Phase 3 readout in December 2025, showing 28.7% weight loss and 75.8% pain reduction at 68 weeks.

Who researches Retatrutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    Triple GLP-1/GIP/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • Those with History of pancreatitis

    High

    GLP-1 component carries pancreatitis risk.

  • Those with Severe gastroparesis

    High

    GLP-1 component significantly slows gastric emptying.

  • Those who are pregnant or breastfeeding

    Absolute

    Investigational — no reproductive safety data.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    Triple GLP-1/GIP/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • History of pancreatitis

    High

    GLP-1 component carries pancreatitis risk.

  • Severe gastroparesis

    High

    GLP-1 component significantly slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Investigational — no reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(7)

Rated by level of concern

  • Gastrointestinal adverse events

    High

    PMID 37366315; PMID 37385280; PMID 42250575

  • Dysesthesia (altered skin sensation)

    Moderate

    Lilly TRIUMPH-4 topline report: https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

  • Dose-dependent increase in heart rate

    Moderate

    PMID 37366315; NCT06383390

  • Pancreatitis (rare)

    Low

    PMID 40291085; PMID 37385280 (class-based inference)

  • Gallbladder events (cholelithiasis)

    Moderate

    Class evidence + weight-loss magnitude (PMID 37366315); retatrutide-specific rates unpublished

  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical

    GLP-1 receptor agonist class labeling (FDA); no retatrutide-specific human data

  • Limited long-term safety data

    High

    NCT05929066; NCT06383390; PMID 41090431

Interaction summary(8)

Rated by direction with this peptide

  • Insulin and sulfonylureas

    CautionModerate

    Adding retatrutide's glucose-lowering effect to insulin or an insulin secretagogue meaningfully raises hypoglycemia risk and generally requires pre-emptive down-titration of the background agent, as is standard across the incretin class; notably, no severe hypoglycemia occurred in the Phase 2 or Phase 3 T2D trials where background therapy was managed per protocol.

    PMID 37385280 (Lancet 2023); PMID 42250575 (TRANSCEND-T2D-1); GLP-1 class labeling

  • Narrow-therapeutic-index oral drugs (warfarin, levothyroxine, antiepileptics)

    CautionLow

    Delayed gastric emptying can alter the rate and extent of oral absorption, and Lilly ran a dedicated Phase 1 DDI cocktail study of midazolam, warfarin and caffeine with retatrutide (NCT05445232, completed Feb 2023) — results are not publicly posted, so monitoring (e.g. INR, TSH) during dose escalation is prudent rather than evidence-mandated.

    NCT05445232; https://clinicaltrials.gov/study/NCT05445232

  • Anesthesia and procedural sedation

    CautionModerate

    Delayed gastric emptying can leave retained gastric contents despite standard fasting, creating aspiration risk during general anesthesia or deep sedation; anesthesiology guidance for GLP-1 receptor agonists advises holding weekly agents before elective procedures, and retatrutide's triple agonism gives no reason to expect less gastric slowing.

    ASA guidance on GLP-1 receptor agonists (class-based); PMID 37366315 (gastric effects)

  • Other incretin agonists (semaglutide, tirzepatide, liraglutide)

    CautionModerate

    Concomitant use has never been studied and offers no expected additive benefit while increasing GI adverse event, heart-rate and hypoglycemia risk; Lilly's own Phase 3 program treats these as alternatives, not partners (retatrutide vs tirzepatide, NCT06662383; vs semaglutide, TRANSCEND-T2D-2, NCT06260722).

    NCT06662383; NCT06260722

  • Antihypertensives and diuretics

    CautionLow

    Retatrutide lowers systolic blood pressure by roughly 10 mmHg on its own, so existing antihypertensives may need down-titration to avoid hypotension, and the combination of diuretics with vomiting or diarrhoea from GI adverse events can produce volume depletion and prerenal acute kidney injury.

    PMID 40291085 (meta-analysis, SBP -9.88 mmHg)

  • Metformin and SGLT2 inhibitors

    NeutralLow

    These were permitted background therapies throughout the Phase 2 and Phase 3 type 2 diabetes programs with no interaction signal reported, making them the best-characterized safe co-medications; SGLT2 inhibitors do add an independent volume-depletion consideration during GI adverse events.

    PMID 37385280; PMID 42250575

  • Oral contraceptives

    CautionTheoretical

    Tirzepatide, the other GIP receptor agonist, carries a labeled interaction reducing oral contraceptive exposure and advises a non-oral backup method during initiation and dose escalation; retatrutide's shared GIP agonism and gastric-emptying effects make the same concern mechanistically plausible, but no retatrutide-specific contraceptive PK data have been published.

    Tirzepatide (Mounjaro/Zepbound) FDA label, class-based extrapolation; no retatrutide-specific data

  • Beta-blockers (metoprolol)

    CautionTheoretical

    Lilly completed a dedicated Phase 1 study of retatrutide's effect on metoprolol pharmacokinetics (NCT06808802, completed April 2025) whose results are not yet public; separately, beta-blockade may blunt or offset retatrutide's dose-dependent heart-rate rise, which is a pharmacodynamic overlap rather than a demonstrated adverse interaction.

    NCT06808802; https://clinicaltrials.gov/study/NCT06808802

Known risks(7)

  • Gastrointestinal adverse events

    Mild to Moderate

    Nausea (38-43%), diarrhea (33-35%), vomiting (20-21%), constipation (22-25%) at the higher doses in Phase 3. Dose-related; partially mitigated by slower dose escalation.

  • Dysesthesia (altered skin sensation)

    Mild

    New Phase 3 finding: 8.8% and 20.9% in the two highest-dose arms vs 0.7% placebo in TRIUMPH-4. Generally mild.

  • Dose-dependent increase in heart rate

    Mild to Moderate

    Heart rate increased 5-10 bpm, peaking around week 24. Consistent with GLP-1 class.

  • Pancreatitis (rare)

    Serious / Rare

    Acute pancreatitis reported in ~0.4% of Phase 2 participants. Consistent with GLP-1 class risk. Monitor lipase/amylase.

  • Gallbladder events (cholelithiasis)

    Moderate

    ~1.1% of retatrutide patients vs 0% placebo in Phase 2. Rapid weight loss is a known gallstone risk factor.

  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical

    All GLP-1 agonists carry a class precaution based on rodent thyroid C-cell tumors. Not confirmed in humans but expected as boxed warning if approved.

  • Limited long-term safety data

    Lilly has reported treatment through 104 weeks in a selected TRIUMPH-1 extension cohort; long-term safety, including cardiovascular, cancer, and bone density effects, remains incompletely characterized.

Drug interactions(5)

  • Insulin and insulin secretagogues

    May increase hypoglycemia risk. Dose adjustments of diabetes medications likely required.

  • Other GLP-1 or incretin-based agonists

    Co-administration not recommended — overlapping mechanisms, additive GI side effects.

  • Oral medications with narrow therapeutic index (warfarin, digoxin, levothyroxine)

    Slowed gastric emptying may alter absorption. Monitor levels during dose escalation.

  • Oral contraceptives

    Delayed gastric emptying may reduce absorption. Backup contraception advised during dose escalation.

  • Antihypertensive medications

    Retatrutide reduced systolic BP by up to 14.0 mmHg. May require dose reduction to avoid hypotension.

Research & benefits

Evidence base

Evidence Level
Strong Evidence
Total Studies
12
Human Participants
7000

Phase 2 results published in NEJM, Lancet, and Nature Medicine. Phase 3 TRIUMPH program has 8+ trials enrolling 5,800+ participants. Five positive Phase 3 studies reported: TRIUMPH-1, -2, -3, -4 and TRANSCEND-T2D-1. Not yet FDA-approved.

Researched for(6)

Rated by confidence in the evidence

  • Record-setting weight loss (up to 24.2% at 48 weeks Phase 2; 28.7% at 68 weeks Phase 3)

    High

    Confirmed in a Phase 2 randomized trial; the higher Phase 3 figures are unpublished company data.

    PMID 37366315 (N Engl J Med 2023, Phase 2); NCT05929066 / NCT05931367 (Phase 3, topline only); https://pubmed.ncbi.nlm.nih.gov/37366315/

  • Dramatic liver fat reduction — 86% of MASLD patients achieved normal liver fat at 24 weeks

    High

    Phase 2a trial: 86% on the highest dose reached normal liver fat by week 24.

    PMID 38858523 (Nat Med 2024, Sanyal et al., phase 2a retatrutide MASLD trial); https://pubmed.ncbi.nlm.nih.gov/38858523/

  • Substantial HbA1c reduction in type 2 diabetes (up to 2.02% at 24 weeks)

    High

    Phase 2 randomized trial showed a 2.02% HbA1c drop, later confirmed in a 2026 Phase 3 trial.

    PMID 37385280 (Lancet 2023); PMID 42250575 (Lancet 2026, TRANSCEND-T2D-1)

  • Significant osteoarthritis pain relief (75.8% WOMAC pain score reduction)

    Medium

    A Phase 3 trial measured this outcome, but the 75.8% figure is from unpublished company reporting.

    NCT05931367; PMID 41090431 (Diabetes Obes Metab 2026, TRIUMPH design paper); Lilly topline (unpublished)

  • Cardiovascular risk marker improvements (blood pressure, lipids, hsCRP)

    High

    Meta-analysis and trials show blood pressure and lipid gains; preliminary cardiovascular event analyses have been reported, without demonstrated benefit.

    PMID 40291085 (Proc Bayl Univ Med Cent 2025, meta-analysis); PMID 37366315; NCT06383390

  • Favorable body composition — preferential fat loss over lean mass

    High

    A Phase 2 body-composition substudy found fat loss dominates, though lean mass loss is still notable.

    PMID 40609566 (Lancet Diabetes Endocrinol 2025)

Benefits(6)

  • Record-setting weight loss (up to 24.2% at 48 weeks Phase 2; 28.7% at 68 weeks Phase 3)

    Phase 2 (Jastreboff, NEJM 2023, n=338): 12 mg achieved 24.2% at 48 weeks. Phase 3 TRIUMPH-4 (n=445): 12 mg achieved 28.7% at 68 weeks.

  • Dramatic liver fat reduction — 86% of MASLD patients achieved normal liver fat at 24 weeks

    Sanyal et al., Nature Medicine 2024, n=98: 12 mg reduced liver fat by 82-86%; 86% achieved normal levels (<5%) vs 0% placebo.

  • Substantial HbA1c reduction in type 2 diabetes (up to 2.02% at 24 weeks)

    Rosenstock et al., Lancet 2023, n=281: 12 mg reduced HbA1c by 2.02% at 24 weeks, exceeding dulaglutide.

  • Significant osteoarthritis pain relief (75.8% WOMAC pain score reduction)

    TRIUMPH-4 Phase 3 (n=445): 9 mg reduced WOMAC pain by 75.8% vs 40.3% placebo at 68 weeks.

  • Cardiovascular risk marker improvements (blood pressure, lipids, hsCRP)

    TRIUMPH-4: 12 mg lowered systolic BP by 14.0 mmHg with reductions in non-HDL cholesterol, triglycerides, and hsCRP.

  • Favorable body composition — preferential fat loss over lean mass

    Body composition substudy (Lancet Diabetes & Endocrinology 2025; 189 enrolled, 155 with baseline DXA, 103 with both scans): 8 mg reduced total fat mass by 26.1% vs 4.5% placebo.

Key studies(4)

  1. Jastreboff AM, Kaplan LM, Frias JP, et al.

    New England Journal of Medicine

    2023

    Dose-dependent weight loss: 24.2% at 12 mg vs 2.1% placebo at 48 weeks. No plateau observed. 100% of 12 mg patients achieved >=5% weight loss.

  2. Rosenstock J, Frias JP, Rodbard HW, et al.

    The Lancet

    2023

    HbA1c reduction of 2.02% at 24 weeks (12 mg) vs -0.01% placebo. Weight loss up to 16.94% at 36 weeks.

  3. Sanyal AJ, Kaplan LM, Frias JP, et al.

    Nature Medicine

    2024

    Liver fat reduced by 82-86% at 8-12 mg doses. 86% achieved normal liver fat (<5%) at 12 mg vs 0% placebo at 24 weeks.

  4. Eli Lilly and Company

    Eli Lilly press release / ClinicalTrials.gov

    2025

    28.7% weight loss at 12 mg; 75.8% WOMAC pain reduction at 9 mg. Systolic BP reduced by 14.0 mmHg.

What research suggests over time

  • Weeks 2-4

    Phase 2 NEJM 2023

    Rapid appetite reduction and early weight loss as dose escalation begins.

  • Months 2-3

    Phase 2 NEJM 2023

    ~9-15% body weight reduction at the higher trial doses by week 12-24.

  • Long-term

    Phase 2/3 RCT

    Mean 24.2% weight loss at 48 weeks (highest-dose arm, Phase 2); 28.7% at 68 weeks in Phase 3 TRIUMPH-4.

Regulation & availability

Why researchers look at it

Retatrutide has produced the most dramatic weight loss results ever in obesity drug trials — 28.7% in Phase 3 — by adding glucagon receptor activation on top of GIP/GLP-1. Its MASLD data (86% liver fat normalization) is unprecedented. With Phase 3 results in 2026 and potential FDA approval in 2027, it is the most closely watched obesity drug in development.

Estimated cost
Not yet available — Phase 3 trials ongoing (Eli Lilly)
FDA status
Retatrutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. Lilly plans a Biologics License Application submission in Q1 2027. Approval timing is unconfirmed.
WADA status
Not explicitly listed by name but effectively prohibited under S0 (Non-Approved Substances) as an unapproved investigational drug.
Prescribability
No — Investigational (Phase 3 ongoing)
Availability
Access limited to clinical trial enrollment.

International status

  • EU

    Phase 3 trials

  • US

    Phase 3 trials (Eli Lilly)

  • Worldwide

    Investigational — not yet approved anywhere

Regulatory timeline(9)

  1. 2022-11
    Phase 1b results published in The Lancet — ~10% weight loss at 12 mg in 12 weeks
  2. 2023-06
    Phase 2 obesity results published in NEJM — up to 24.2% weight loss at 48 weeks
  3. 2023-06
    Phase 2 T2D results published in The Lancet — HbA1c -2.02%, weight -16.9% at 36 weeks
  4. 2023-H2
    Phase 3 TRIUMPH program initiated — 8+ trials, 5,800+ participants
  5. 2024-06
    MASLD results published in Nature Medicine — 86% liver fat normalization
  6. 2025-12
    TRIUMPH-4 Phase 3 topline results — 28.7% weight loss, 75.8% OA pain reduction
  7. 2026-03
    TRANSCEND-T2D-1 Phase 3 results — HbA1c -1.7 to -2.0%, 16.8% weight loss
  8. 2026-05-21
    Positive TRIUMPH-1 topline results announced.
  9. 2027-2028 (expected)
    Potential FDA approval

Sources & FAQs

Research sources(5)

Frequently asked questions(4)

How does retatrutide compare to semaglutide and tirzepatide?

Retatrutide activates three receptors (GIP, GLP-1, glucagon) vs one for semaglutide and two for tirzepatide. It has produced the largest weight reductions ever recorded: 28.7% at 68 weeks vs ~15% for semaglutide and ~22% for tirzepatide. The glucagon component adds energy expenditure and liver fat burning beyond the other drugs. No head-to-head trials exist.

When will retatrutide be available?

Phase 3 trials are reading out throughout 2025-2026. If positive, Lilly plans a BLA submission in Q1 2027; approval timing remains unconfirmed. It cannot legally be compounded or sold outside clinical trials.

Can retatrutide treat fatty liver disease?

Phase 2 data is extremely promising: 86% of MASLD patients achieved normal liver fat at the highest dose. A dedicated MASLD Phase 3 trial is part of the TRIUMPH program.

What are the main side effects?

GI symptoms are most common: nausea (38-43%), diarrhea (33-35%), vomiting (20-21%). A new Phase 3 finding was dysesthesia (altered skin sensation) in up to 21%. Slower dose escalation partially mitigates GI symptoms.